PMID- 23550839
OWN - NLM
STAT- MEDLINE
DCOM- 20141104
LR  - 20151119
IS  - 1600-0404 (Electronic)
IS  - 0001-6314 (Linking)
VI  - 128
IP  - 5
DP  - 2013 Nov
TI  - Clinical and biomarker assessment of demyelinating events suggesting multiple 
      sclerosis.
PG  - 336-44
LID - 10.1111/ane.12123 [doi]
AB  - BACKGROUND: Initial demyelinating event (IDE) diagnosis and prognosis are not 
      straightforward. OBJECTIVE: To identify potential diagnostic markers and outcome 
      predictors of IDEs suggestive of multiple sclerosis (MS), that is, clinically 
      isolated syndromes (CISs). METHODS: Clinically isolated syndrome cases (i.e., 
      subjects with an IDE compatible with MS onset and no alternative explanation) 
      with at least 1.5 years' follow-up were retrospectively identified. All cases 
      underwent clinical, neurophysiological, MRI, and cerebrospinal fluid (CSF) 
      assessment, including exploratory tau, 14-3-3, and cystatin C testing. CIS 
      recovery, conversion to MS, and long-term neurological disability were used as 
      outcome measures. Patients with neuromyelitis optica spectrum disorders, 
      idiopathic acute transverse myelitis (IATM), Creutzfeldt-Jacob disease, and 
      non-inflammatory/non-neurodegenerative disorders served as controls for CSF 
      analysis. RESULTS: Forty-six CIS cases were included. Severe presentation was 
      associated with incomplete recovery, while presence of at least 3 periventricular 
      lesions on baseline MRI correlated with MS conversion. Initial pyramidal tract 
      involvement, incomplete CIS recovery, and number of relapses predicted 
      neurological disability. CSF tau, 14-3-3, and cystatin C did not correlate with 
      any outcome measure. CIS cases had significantly lower tau and cystatin C levels 
      compared to IATM. CONCLUSIONS: An extensive diagnostic evaluation of patients 
      with an IDE is worthwhile to make prognostic predictions. More robust molecular 
      biomarkers are needed.
CI  - (c) 2013 John Wiley & Sons A/S.
FAU - Gajofatto, A
AU  - Gajofatto A
AD  - Section of Clinical Neurology, Department of Neurological, Neuropsychological, 
      Morphological and Movement Sciences, University of Verona, Italy.
FAU - Bongianni, M
AU  - Bongianni M
FAU - Zanusso, G
AU  - Zanusso G
FAU - Bianchi, M R
AU  - Bianchi MR
FAU - Turatti, M
AU  - Turatti M
FAU - Benedetti, M D
AU  - Benedetti MD
FAU - Monaco, S
AU  - Monaco S
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130401
PL  - Denmark
TA  - Acta Neurol Scand
JT  - Acta neurologica Scandinavica
JID - 0370336
RN  - 0 (14-3-3 Proteins)
RN  - 0 (Biomarkers)
RN  - 0 (Nerve Tissue Proteins)
RN  - 0 (Oligoclonal Bands)
RN  - 0 (tau Proteins)
SB  - IM
MH  - 14-3-3 Proteins/cerebrospinal fluid
MH  - Adult
MH  - Biomarkers/*cerebrospinal fluid
MH  - *Demyelinating Diseases/cerebrospinal fluid/diagnosis/etiology
MH  - Disability Evaluation
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Female
MH  - Humans
MH  - Magnetic Resonance Imaging
MH  - Male
MH  - Middle Aged
MH  - Multiple Sclerosis/*complications
MH  - Nerve Tissue Proteins/cerebrospinal fluid
MH  - Oligoclonal Bands/cerebrospinal fluid
MH  - Predictive Value of Tests
MH  - Statistics as Topic
MH  - tau Proteins/cerebrospinal fluid
OTO - NOTNLM
OT  - clinical outcome
OT  - clinically isolated syndrome
OT  - multiple sclerosis
EDAT- 2013/04/05 06:00
MHDA- 2014/11/05 06:00
CRDT- 2013/04/05 06:00
PHST- 2013/02/11 00:00 [accepted]
PHST- 2013/04/05 06:00 [entrez]
PHST- 2013/04/05 06:00 [pubmed]
PHST- 2014/11/05 06:00 [medline]
AID - 10.1111/ane.12123 [doi]
PST - ppublish
SO  - Acta Neurol Scand. 2013 Nov;128(5):336-44. doi: 10.1111/ane.12123. Epub 2013 Apr 
      1.